ФИЗИОЛОГИЧЕСКАЯ РОЛЬ И КЛИНИЧЕСКИЕ ЭФФЕКТЫ МЕЛАТОНИНА

Скачать статью в PDF
Номер журнала: 
3
Год издания: 
2015

С. Леваков, Е. Боровкова Первый МГМУ им. И.М. Сеченова E-mail: katyanikitina@mail.ru

Мелатонин обладает широким спектром активности, но основная его функция – нормализация сна. Приводятся данные клинических исследований, позволяющие расширить показания к применению препаратов мелатонина.
Ключевые слова: 
мелатонин
клинические эффекты мелатонина
Для цитирования
Леваков С., Боровкова Е. ФИЗИОЛОГИЧЕСКАЯ РОЛЬ И КЛИНИЧЕСКИЕ ЭФФЕКТЫ МЕЛАТОНИНА . Врач, 2015; (3): 72-75

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

Список литературы: 
  1. Ariens-Kappers J. Innervation of the Epiphysis cerebri in the albino rat // Anat. Rec. – 1960; 136: 220
  2. Axelrod J., Shein H., Wurtman R. Stimulation of C14-melatonin synthesis from C14-tryptophan by noradrenaline in rat pineal in organ culture // Proc. Natl. Acad. Sci. USA. – 1969; 62: 544.
  3. Anisimov V., Alimova I., Baturin D. et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice // Exp. Gerontol. – 2003; 38: 449.
  4. Aoki H., Yamada N., Ozeki Y. et al. Minimum light intensity required to suppress nocturnal melatonin concentration in human saliva // Neurosci. Lett. – 1998; 252: 91.
  5. Atkinson G., Jones H., Edwards B. et al. Effects of daytime ingestion of melatonin on short-term athletic performance // Ergonomics. – 2005; 48: 1512.
  6. Bonn, D. Melatonin's multifarious marvels: Miracle or myth? // Lancet. – 1996; 347: 184.
  7. Brzezinski A. Melatonin in humans // N. Engl. J. Med. – 1997; 336: 186.
  8. Brzezinski A., Vangel M., Wurtman R. et al. Effects of exogenous melatonin on sleep: a meta-analysis // Sleep Med. Rev. – 2005; 9: 41.
  9. Buscemi N., Vandermeer B., Pandya R. et al. Melatonin for treatment of sleep disorders. Summary, evidence report/technology assessment: Number 108. AHRQ Publication Number 05-E002-1, November 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcsums/melatsum.htm (Accessed on September 23, 2011).
  10. Buscemi N., Vandermeer B., Hooton N. et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis // J. Gen. Intern. Med. – 2005; 20: 1151.
  11. Cagnacci A., Cannoletta M., Renzi A. et al. Prolonged melatonin administration decreases nocturnal blood pressure in women // Am. J. Hypertens. – 2005; 18: 1614.
  12. Duell P., Wheaton D., Shultz A. et al. Inhibition of LDL oxidation by melatonin requires supraphysiologic concentrations // Clin. Chem. – 1998; 44: 1931–36.
  13. Ekman A., Leppäluoto J., Huttunen P. et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study // J. Clin. Endocrinol. Metab. – 1993; 77: 780.
  14. Erman M., Seiden D., Zammit G. et al. An efficacy, safety, and doseresponse study of Ramelteon in patients with chronic primary insomnia // Sleep Med. – 2006; 7: 17.
  15. Fiske V., Bryant K., Putnam J. Effect of light on the weight of pineal in the rat // J. Endocrinol. – 1960; 66: 489.
  16. Grossman E., Laudon M., Yalcin R. et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension // Am. J. Med. – 2006; 119: 898.
  17. Gerdin M., Masana M., Rivera-Bermúdez M. et al. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin // FASEB J. – 2004; 18: 1646.
  18. Gerdin M., Masana M., Dubocovich ML. Melatonin-mediated regulation of human MT(1) melatonin receptors expressed in mammalian cells // Biochem. Pharmacol. – 2004; 67: 2023–30.
  19. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders // Curr. Opin. Investig. Drugs. – 2009; 10: 691.
  20. Jonas M., Garfinkel D., Zisapel N. et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients // Blood Press. – 2003; 12: 19.
  21. Kitay J., Altschule M. Effects of pineal extract administration on ovary weight in rats // Endocrinol. – 1954; 55: 782
  22. Klein D. The pineal gland: A model of neuroendocrine regulation. In: The Hypothalamus, Reichlin S., Baldessarini R., Martin J. (Eds) / New York: Raven Press, 1978; p. 303.
  23. Kopin I., Pare C., Axelrod J., et al. 6-Hydroxylation, the major metabolic pathway for melatonin // Biochim. Biophys. Acta. – 1960; 40: 377.
  24. Kennaway D., Stamp G., Goble F. Development of melatonin production in infants and the impact of prematurity // J. Clin. Endocrinol. Metab. – 1992; 75: 367.
  25. Lewy A., Wehr T., Goodwin F. et al. Lights up presses melatonin secretion in humans // Science. – 1980; 210: 1267
  26. Lerner A., Case J., Takahashi Y. et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes // J. Am. Chem. Soc. – 1958; 80: 2587.
  27. Lynch H.. Diurnal oscillations in pineal melatonin content // Life Sci. – 1971; 27. 10: 791
  28. Lynch H., Wurtman R., Moskowitz M. et al. Daily rhythm in human urinary melatonin // Science. – 1975; 187: 169.
  29. Lynch H., Jimerson D., Ozaki Y. et al. Entrainment of rhythmic melatonin secretion in man to a 12-hour phase shift in the light/dark cycle // Life Sci. – 1978; 23: 1557.
  30. Moore R., Klein D. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity // Brain Res. – 1974; 71: 17.
  31. Pappolla M., Bozner P., Soto C. et al. Inhibition of Alzheimer beta fibrillogenesis by melatonin // J. Biol. Chem. – 1998; 273: 7185.
  32. Pappolla M., Chyan Y., Poeggeler B. et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease // J. Neural. Transm. – 2000; 107: 203.
  33. Rodriguez C., Mayo J., Sainz R. et al. Regulation of antioxidant enzymes: a significant role for melatonin // J. Pineal. Res. – 2004; 36: 1.
  34. R34. öjdmark S., Wikner J., Adner N. et al. Inhibition of melatonin secretion by ethanol in man // Metabolism. – 1993; 42: 1047.
  35. Tricoire H., Locatelli A., Chemineau P. et al. Melatonin enters the cerebrospinal fluid through the pineal recess // Endocrinology. – 2002; 143: 84.
  36. Waldhauser F., Lynch H., Wurtman R. Melatonin in human body fluids: Clinical significance. In: The Pineal Gland (Comprehensive Endocrinology), Reiter R. (Ed) / New York: Raven Press, 1984; p. 345.
  37. Waldhauser F., Lieberman H., Lynch H. et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol // Neuroendocrinology. – 1987; 46: 125.
  38. Wang L., Suthana N., Chaudhury D. et al. Melatonin inhibits hippocampal long-term potentiation // Eur. J. Neurosci. – 2005; 22: 2231.